- This material is a translation of the press release announced on February 23, 2011 into English, and Japanese is given to priority about the content and the interpretation.

February 23, 2011

Transdermal Pain Reliever and Anti-Inflammatory "Mohrus Tape" ⊚ (Development Code: KPT-220)

Notice Pertaining the Acquisition of Approval to Add the Effects Related to "Pain and Inflammation Relief for Acute Disorders and Symptoms"

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture President: Hirotaka NAKATOMI) announces that effective today it has obtained approval to add the effects related to "pain and inflammation relief for acute disorders and symptoms (muscle pain, swelling and pain due to external injuries)" to the transdermal pain reliever and anti-inflammatory "Mohrus Tape_\$ 20 mg." and "Mohrus Tape $L_\$$ 40 mg." (Common Name: ketoprofen, henceforth "Mohrus Tape)

In December 1995, "Mohrus Tape" was the first in Japan to obtain approval as a skin patch indicated for lower back pain along with "osteoarthritis" and "shoulder periarthritis." In addition, in November 2009 it was additionally indicated for "rheumatoid arthritis."

We think that with the recent addition of "acute disorders" to "chronic disorders" "Mohrus Tape" can contribute to pain relief treatments for even more patients.

<Reference>

[The Effects and Effectiveness of "Mohrus Tape_® 20mg" and "Mohrus Tape L_® 40 mg"]

OPain and inflammation relief from the following disorders and symptoms

Lower back pain (muscle/myofascial, osteoarthritis of the spine, intervertebral disc disease, lumbar strain), osteoarthritis, shoulder periarthritis, tendon/tendonitis, inflammation around the tendon, humeral epicondylitis (tennis elbow, etc.), muscle pain and swelling and aches caused by external injuries.

OLocalized joint pain relief in rheumatoid arthritis